Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform.

Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well as Wellington Partners and new investor Amgen.

Late-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.

Scotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair.

Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.

The European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration!

Belgian nanobody developer Ablynx NV’s nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP),  paving the way to market authorisation in Europe and the US.

Active sampling of airborne viruses, bacteria, yeasts and fungi.

Symcel announced that Jesper Ericsson has joined Symcel as Chief Executive Officer. 

A newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity.